Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03931564
Other study ID # NL68964.068.19
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date December 1, 2024

Study information

Verified date October 2023
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The standard surgical treatment for glaucoma is trabeculectomy. The PRESERFLOâ„¢ (formerly InnFocus) Microshunt (IMS) is a new, minimally invasive drainage device which has been suggested to result in similar IOP lowering, but with faster visual recovery and less complications and postoperative interventions. The objective of this study is to aid in deciding on the use of the IMS in glaucoma surgery by assessing its efficacy and cost-effectiveness in patients with primary open angle glaucoma (POAG) compared to the standard trabeculectomy (TE).


Description:

During the last decade, minimally invasive glaucoma surgery (MIGS) procedures have been introduced to the market. MIGS procedures or devices, often small stents or tubes that can be placed into the eye, are potentially safer than standard trabeculectomy (TE). The surgery is faster and easier to perform. Patient recovery is faster with fewer postoperative visits, suggesting less impact on vision and quality of life. However, MIGS devices are more expensive compared to standard surgery and it is unclear if the higher costs can be compensated with their better safety profile and faster patient recovery (reduced productivity losses). To establish guidelines for the use of MIGS, the Netherlands Glaucoma Group has recognized the need for a formal investigation of their cost-effectiveness as compared to TE, prior to their implementation on a large scale for regular care. Therefore, a societal cost-effectiveness analysis of MIGS procedures will be undertaken to further elucidate their position in the glaucoma treatment algorithm in the Netherlands. The objective of this study is to aid in deciding on the use of the IMS in glaucoma surgery by assessing its efficacy and cost-effectiveness in patients with primary open angle glaucoma compared to trabeculectomy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 124
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Adult Caucasian patients aged between 18 and 80 years old with uncontrolled primary open angle glaucoma on (maximum tolerated) medical therapy and/or progression of visual field loss, an IOP =18 and =40 mmHg, and an indication for primary glaucoma surgery (trabeculectomy) are suitable for inclusion. Exclusion Criteria: 1. Patient unwilling or unable to give informed consent, unwilling to accept randomization or inability to complete follow-up (e.g. hospital visits) or comply with study procedures 2. Secondary glaucoma (e.g. pigment dispersion syndrome, pseudo exfoliation syn-drome, iris neovascularization, rubeosis iridis, trauma, epithelial or fibrous down growth, iridocorneal endothelial syndrome, etcetera). 3. Previous incisional surgery of the subject eye. Previous uncomplicated clear corneal cataract surgery is allowed >6 months prior to the surgery. 4. Poor vision in either the study or fellow eye. Poor vision is defined as a corrected vis-ual acuity <0.6 and/or a visual field loss within the central 10 degrees (with exception of a superior altitudinal defect). 5. Any ocular comorbidities that could affect the visual field. (e.g. diabetic retinopathy, proliferative retinopathy, aphakia, degenerative visual disorder not associated with glaucoma) 6. Chronic or recurrent uveitis. 7. Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery. 8. Anatomical factors that increase the risk of complicated surgery (due to previous trauma, anatomical abnormalities, anterior synechiae or previous cyclodestructive procedure). 9. Conditions that increase the risk of endophthalmitis. - Current ocular, adnexal or periocular infections (e.g., untreated blepharitis) - Immune compromised patients including the use of topical or systemic steroids for an indication other than the surgery within 3 months of the procedure (this would not include the use of inhaled or dermatologic steroids), chemotherapy within 6 months of the procedure. - Iodine allergy - Unwilling to discontinue contact lens after surgery 10. Contraindication or allergy to mitomycin C. 11. Any contraindication to tube placement (e.g. shallow anterior chamber, insufficient endothelial cell density). 12. Use of oral hypotensive glaucoma medications for treatment of the fellow eye. 13. Prior ocular laser treatment within 3 months of the surgery, increasing the risk of in-flammation in the eye. 14. Corneal thickness <450um or >620microns. 15. Conditions associated with elevated episcleral venous pressure such as active thyroid orbitopathy. 16. Among patients in whom both eyes are eligible only the first eye is undergoing surgical treatment is enrolled in the study. 17. Participation in another clinical study.

Study Design


Intervention

Procedure:
PRESERFLO Microshunt implantation
The intervention consists of the microshunt implantation augmented with mitomycin C application.
Trabeculectomy
The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.

Locations

Country Name City State
Netherlands Maastricht University Medical Center+ (MUMC+) Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular pressure The intraocular pressure is measured using a Goldmann applanation tonometer 12 months postoperatively
Secondary Visual acuity Measured with ETDRS letter charts baseline, 1 week, 4 weeks, 3, 6, 9 and 12 months postoperatively
Secondary Glaucoma medical therapy number of glaucoma drugs (active substances) at baseline and 1 day, 1 week, 4 weeks, 3, 6, 9 and 12 months postoperatively
Secondary Failure rate Failure is defined as an IOP >21 mmHg and = 5 mmHg or less than 20% reduction relative to baseline IOP at two consecutive follow-up visits after 3 months. Reoperation will also be defined as failure. 3, 6, 9 and 12 months postoperatively
Secondary Complications The incidence of intraoperative and postoperative complications. Intraoperatively and up to 12 months after the surgery.
Secondary Reinterventions The number of reinterventions after the surgery. Measured up to 12 months after the surgery.
Secondary Visual field progression The progression seen on the visual field. measured twice at baseline and twice after 12 months of follow-up.
Secondary Mean endothelial cell loss The endothelial cell density will be measured using specular microscopy photography. measured at baseline and after 12 months of follow-up.
Secondary Patient- reported outcome measures (PROMs): NEI-VFQ-25 Patient satisfaction and vision-specific quality of life as measured by National Eye Institute Visual Function Questionnaire (NEI VFQ-25). measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively
Secondary Patient- reported outcome measures (PROMs): GQL-15 Patient satisfaction and vision-specific quality of life as measured by Glaucoma Quality of Life-15 (GQL-15). measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively
Secondary Patient- reported outcome measures (PROMs): EuroQol's EQ-5D-5L Health-related quality of life as measured by EuroQol's EQ-5D-5L questionnaire. measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively
Secondary Patient- reported outcome measures (PROMs): HUI3 Health-related quality of life as measured by HUI3 (Health Utility Index Mark 3) questionnaire. measured at baseline, 4 weeks, 3, 6, and 12 months postoperatively
Secondary Quality Adjusted Life Years (QALYs) Calculated based on generic health-related quality of life, using the EQ-5D-5L and HUI-3 questionnaires Baseline until 12 months postoperatively
Secondary Costs per patient Cost per patient, including valuation of resource use by using the Dutch guidelines for cost-analyses or cost prices provided by the medical center. Baseline until 12 months postoperatively
Secondary Incremental cost-effectiveness ratios (ICERs): QALY Evaluation of cost-effectiveness by using calculated costs per quality-adjusted life years (QALYs) Baseline until 12 months postoperatively
Secondary Incremental cost-effectiveness ratios (ICERs): NEI VFQ-25 Calculated costs per clinically improved patient on the NEI VFQ-25 questionnaire Baseline until 12 months postoperatively
Secondary Incremental cost-effectiveness ratios (ICERs): GQL-15 Calculated costs per clinically improved patient on the GQL-15 questionnaire Baseline until 12 months postoperatively
Secondary Incremental cost-effectiveness ratios (ICERs): IOP Calculated costs per patient with clinically lowered IOP Baseline until 12 months postoperatively
Secondary Budget impact Reported as a difference in costs. Different scenario's will be compared to investigate the impact of various levels of implementation (e.g. 25%, 50%, 75% of eligible patients). Baseline until 12 months postoperatively
See also
  Status Clinical Trial Phase
Completed NCT01841437 - Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry N/A
Completed NCT02077231 - Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients N/A
Completed NCT01410188 - Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension Phase 1/Phase 2
Recruiting NCT05557058 - GORE Glaucoma Drainage Implant Clinical Study N/A
Not yet recruiting NCT03924544 - Decorin in Sub Scleral Trabeculectomy Phase 1
Active, not recruiting NCT03673644 - Impact of Glaucoma and Visual Field Loss on Life Space
Completed NCT03365778 - Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment N/A
Completed NCT01915940 - Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension Phase 2
Completed NCT03889652 - Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
Terminated NCT03273907 - Post Approval Study of the CyPass System N/A
Recruiting NCT03193333 - PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) Phase 3
Recruiting NCT03921931 - Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study N/A
Not yet recruiting NCT04609345 - Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
Recruiting NCT05264818 - Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
Completed NCT04333433 - PRESERFLO® MicroShunt Extension Study
Enrolling by invitation NCT02144103 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration Phase 1/Phase 2
Completed NCT01281020 - Adherence With Fixed Versus Unfixed Glaucoma Therapy
Recruiting NCT04891588 - Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD N/A
Completed NCT03145129 - PAIR Study-PAP And IOP Relationship: Study 2
Completed NCT03104621 - Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Phase 4